Myung In Pharmaceutical LTD. (KRX:317450)

KRX:317450 Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	283,307	269,435	242,338	225,828	209,250	187,837
Other Revenue	-	-	-	-0	-0	-
Revenue	283,307	269,435	242,338	225,828	209,250	187,837
Revenue Growth (YoY)	16.91%	11.18%	7.31%	7.92%	11.40%	3.33%
Cost of Revenue	110,917	100,556	88,413	82,280	70,954	66,226
Gross Profit	172,390	168,879	153,925	143,549	138,297	121,611
Selling, General & Admin	71,576	67,800	62,249	57,227	57,643	53,001
Research & Development	4,762	3,684	4,037	4,749	2,448	2,651
Amortization of Goodwill & Intangibles	1.16	1.15	0.98	1.25	1.53	1.92
Other Operating Expenses	1,650	1,588	1,485	3,564	1,326	1,236
Operating Expenses	81,829	76,124	70,306	67,646	64,091	56,678
Operating Income	90,561	92,754	83,618	75,903	74,206	64,933
Interest Expense	-268.22	-322.65	-333.54	-106.64	-133.33	-47.92
Interest & Investment Income	9,237	8,621	6,218	2,916	835.94	278.98
Currency Exchange Gain (Loss)	1,461	5,490	1,204	2,687	4,063	-2,932
Other Non Operating Income (Expenses)	187.07	-9,548	527.79	406.58	797.02	904.06
EBT Excluding Unusual Items	101,178	96,994	91,235	81,806	79,768	63,136
Gain (Loss) on Sale of Investments	-8,310	-8,310	826.42	-	-	-
Gain (Loss) on Sale of Assets	-704.09	-609.54	-0.32	10.7	6.39	-3,584
Pretax Income	92,163	88,075	92,061	81,817	79,775	59,552
Income Tax Expense	19,983	19,404	17,550	24,383	20,024	14,074
Net Income	72,180	68,671	74,512	57,434	59,750	45,478
Net Income to Common	72,180	68,671	74,512	57,434	59,750	45,478
Net Income Growth	-3.13%	-7.84%	29.73%	-3.88%	31.38%	6.07%
Shares Outstanding (Basic)	11	11	11	11	11	11
Shares Outstanding (Diluted)	11	11	11	11	11	11
EPS (Basic)	6407.02	6131.31	6652.82	5128.04	5334.82	4060.55
EPS (Diluted)	6407.02	6131.31	6652.82	5128.04	5334.82	4060.55
EPS Growth	-3.69%	-7.84%	29.73%	-3.88%	31.38%	6.07%
Free Cash Flow	55,651	72,783	71,428	57,643	63,407	45,488
Free Cash Flow Per Share	4939.83	6498.51	6377.48	5146.68	5661.37	4061.46
Dividend Per Share	500.000	500.000	2000.000	1000.000	1250.000	1750.000
Dividend Growth	-75.00%	-75.00%	100.00%	-20.00%	-28.57%	-
Gross Margin	60.85%	62.68%	63.52%	63.57%	66.09%	64.74%
Operating Margin	31.97%	34.43%	34.51%	33.61%	35.46%	34.57%
Profit Margin	25.48%	25.49%	30.75%	25.43%	28.55%	24.21%
Free Cash Flow Margin	19.64%	27.01%	29.47%	25.52%	30.30%	24.22%
EBITDA	102,816	105,217	95,058	87,238	85,824	75,894
EBITDA Margin	36.29%	39.05%	39.23%	38.63%	41.02%	40.40%
D&A For EBITDA	12,256	12,463	11,440	11,336	11,619	10,961
EBIT	90,561	92,754	83,618	75,903	74,206	64,933
EBIT Margin	31.96%	34.43%	34.51%	33.61%	35.46%	34.57%
Effective Tax Rate	21.68%	22.03%	19.06%	29.80%	25.10%	23.63%
Advertising Expenses	-	31,186	27,861	25,260	27,110	24,934

Source: S&P Global Market Intelligence. Standard template. Financial Sources.